Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that develops novel antiviral therapeutics targeting the replication process of viruses such as influenza, norovirus, and coronaviruses. Utilizing a unique structure-based drug discovery platform and Nobel Prize-winning expertise, the company aims to create safe, broad-spectrum, resistant, and convenient antiviral drugs. They are advancing multiple clinical programs and discovering new antiviral compounds for high-value indications.
Industries
Nr. of Employees
small (1-50)
Cocrystal Pharma
Patents
Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication
US-12357631-B2
View DetailsPyridopyrazine and pyridotriazine inhibitors of influenza virus replication
US-12037333-B2
View Details
Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication
US-12357631-B2
View DetailsPyridopyrazine and pyridotriazine inhibitors of influenza virus replication
US-12037333-B2
View DetailsProducts
Oral PB2 inhibitor for influenza A (oral small-molecule antiviral)
Orally administered small-molecule inhibitor targeting the PB2 component of influenza A viral replication machinery; progressed through discovery, preclinical and Phase 1 with Phase 2a human challenge study in progress.
Inhaled PB2 inhibitor for influenza A (inhaled small-molecule antiviral)
Inhaled formulation of a PB2-targeting small-molecule antiviral developed for therapeutic and prophylactic use against influenza A; described as advanced through discovery, preclinical and clinical phases.
Oral pan-viral protease inhibitor for norovirus and coronaviruses
Orally administered protease inhibitor intended to act against multiple viruses including norovirus and coronaviruses; reported progression through discovery, preclinical and early clinical (Phase 1) stages.
Broad-spectrum replication inhibitors in discovery
Discovery-stage small-molecule replication enzyme inhibitors aimed at influenza A/B, norovirus and other respiratory viruses to provide broad-spectrum antiviral activity.
CC-31244
A non-nucleoside polymerase inhibitor (NNI) designed as a potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection.
CC-42344
A novel, broad-spectrum antiviral investigational candidate for the treatment of pandemic and seasonal influenza A, targeting the PB2 site of the influenza polymerase complex.
Oral PB2 inhibitor for influenza A (oral small-molecule antiviral)
Orally administered small-molecule inhibitor targeting the PB2 component of influenza A viral replication machinery; progressed through discovery, preclinical and Phase 1 with Phase 2a human challenge study in progress.
Inhaled PB2 inhibitor for influenza A (inhaled small-molecule antiviral)
Inhaled formulation of a PB2-targeting small-molecule antiviral developed for therapeutic and prophylactic use against influenza A; described as advanced through discovery, preclinical and clinical phases.
Oral pan-viral protease inhibitor for norovirus and coronaviruses
Orally administered protease inhibitor intended to act against multiple viruses including norovirus and coronaviruses; reported progression through discovery, preclinical and early clinical (Phase 1) stages.
Broad-spectrum replication inhibitors in discovery
Discovery-stage small-molecule replication enzyme inhibitors aimed at influenza A/B, norovirus and other respiratory viruses to provide broad-spectrum antiviral activity.
CC-31244
A non-nucleoside polymerase inhibitor (NNI) designed as a potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection.
CC-42344
A novel, broad-spectrum antiviral investigational candidate for the treatment of pandemic and seasonal influenza A, targeting the PB2 site of the influenza polymerase complex.
Expertise Areas
- Structure-based drug discovery
- Antiviral drug development
- Structural biology and x-ray crystallography
- Medicinal chemistry and SAR optimization
Key Technologies
- X-ray crystallography
- Protein cocrystallization
- Structure-activity relationship (SAR) analysis
- Enzymology assays